Modified ATT for ATT-Induced Hepatitis
When ATT-induced hepatitis occurs (AST >3× ULN with symptoms OR >5× ULN without symptoms), immediately stop all hepatotoxic drugs (isoniazid, rifampin, and pyrazinamide), then bridge with 2+ non-hepatotoxic agents until liver enzymes normalize to <2× ULN, followed by sequential reintroduction of first-line drugs starting with rifampin. 1
Immediate Management When Hepatitis Develops
Stop All Hepatotoxic Drugs Immediately
- Discontinue INH, RIF, and PZA simultaneously 1
- Definition of hepatitis requiring cessation:
- AST >3× upper limit of normal (ULN) WITH symptoms
- AST >5× ULN WITHOUT symptoms 1
Bridge Therapy During Recovery Phase
Use 2 or more non-hepatotoxic antituberculosis medications until liver function improves 1:
- Ethambutol (EMB)
- Streptomycin (SM) or amikacin/kanamycin
- Fluoroquinolone (levofloxacin, moxifloxacin, or gatifloxacin)
- Capreomycin 1
The combination of these agents prevents disease progression while hepatotoxic drugs are held. This bridging strategy is critical—never leave the patient without effective therapy.
Diagnostic Workup During Recovery
- Test for hepatitis A, B, and C if not done at baseline 1
- Question carefully about alcohol and other hepatotoxins 1
- Monitor AST and bilirubin closely 1
Sequential Reintroduction Protocol
Timing
Begin reintroduction only when:
Reintroduction Sequence
The guideline-recommended approach is sequential reintroduction 1:
- Start with Rifampin first (least hepatotoxic of the three)
- Add Isoniazid second
- Add Pyrazinamide last (if needed)
Close monitoring with repeat AST, bilirubin measurements, and symptom review is essential during each reintroduction step 1.
Alternative Regimens Based on Severity
If Unable to Reintroduce All Three Hepatotoxic Drugs
Option 1: Regimen Without INH (retains 6-month duration)
- Initial phase (2 months): RIF + PZA + EMB (4 drugs if adding fluoroquinolone)
- Continuation phase (4 months): RIF + PZA + EMB 1
- This maintains efficacy even with INH resistance, provided RIF is used throughout 6 months 1
Option 2: Regimen Without PZA (requires 9 months total)
- Initial phase (2 months): INH + RIF + EMB
- Continuation phase (7 months): INH + RIF 1
- Total duration: 9 months 1
For Advanced/Unstable Liver Disease
If only ONE hepatotoxic drug tolerated:
- Retain rifampin (preferred hepatotoxic agent)
- Add: EMB + fluoroquinolone + cycloserine ± injectable agent
- Duration: 12-18 months depending on disease extent 1
If NO hepatotoxic drugs tolerated (severe unstable liver disease):
- Regimen: SM + EMB + fluoroquinolone + second-line oral drug
- Duration: 18-24 months 1
- Expert consultation mandatory for these regimens 1
Critical Monitoring Requirements
Baseline Assessment (Before Starting ATT)
- Liver biochemistry (ALT, AST, ALP, GGT, total/direct bilirubin, albumin) 2
- HBsAg (if positive, add HBV DNA) 2
- Anti-HCV testing 2
- Abdominal imaging 2
During Treatment Monitoring
- High-risk patients: Every 2 weeks for first 2 months, then monthly 2
- Standard-risk patients: Monthly 2
- High-risk factors include: advanced age, female gender, NAT2 slow acetylator, viral hepatitis, HIV, malnutrition, alcohol use 3, 2
Key Principles
Never Add Single Drug to Failing Regimen
Critical pitfall: Never add just one drug to a regimen—this creates functional monotherapy and drives resistance 4. Always add ≥2 drugs to which the organism is susceptible 4.
Benefit-Risk Assessment
The benefit of first-line ATT outweighs monitored risk, so reintroduction should always be attempted after hepatitis resolves 3. However, individualize based on:
- Severity of initial liver injury
- Presence of underlying liver disease
- Tuberculosis disease severity 2
Special Populations
- HIV-infected with CD4 <100: Avoid once-weekly continuation regimens; use daily or 3× weekly 1
- Pregnant/postpartum women: Require ALT monitoring 5
- Chronic hepatitis B or C: Consider antiviral therapy alongside modified ATT 2
The sequential reintroduction approach with close monitoring allows most patients to successfully resume first-line therapy, which remains superior to prolonged second-line regimens in terms of efficacy and treatment duration.